You are here:

rasagiline 1mg tablet monotherapy (Azilect)

Advice

Following a resubmission.

Rasagiline (Azilect®) is not recommended within NHS Scotland for the treatment of idiopathic Parkinson’s disease as monotherapy (without levodopa).

Rasagiline provides modest symptomatic improvement for patients with early Parkinson’s disease. The economic case has not been demonstrated.

Drug Details

Drug Name: rasagiline 1mg tablet monotherapy (Azilect)
SMC Drug ID: 243/06
Manufacturer: Lundbeck Ltd
Indication: Idiopathic Parkinson’s disease as monotherapy (without levodopa)
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 11 December 2006

Archived Advice

Full submission 13 March 2006

Back